Abstract
Background: Multiple sclerosis (MS) patients receive immunomodulatory treatments which can influence their ability to maintain vaccine specific serological response overtime. MS patients treated with cladribine tablets developed a positive serology response following two doses of mRNA COVID-19 vaccine. However, there is only limited data regarding the effect of cladribine tablets on long-term humoral response after the second and the third booster.
Methods: Serology response to SARS-CoV-2 was tested in healthy controls (HCs) and MS patients treated with cladribine tablets 6 and 9-12 months after the second dose, and 1 and 3-6 months following the third booster-dose of the BTN162b2 mRNA vaccine.
Results: Thirty-five out of 36 MS patients treated with cladribine tablets and 100% (46/46) of HCs had a positive serology response up to 10 months after the second vaccine dose. In addition, all cladribine tablets -treated MS patients (22/22) and HCs (24/24) had a positive robust serology response following the third vaccine with a positive humoral response sustain up to 6 months. One month after the third vaccine dose IgG levels were significantly lower in patients treated with cladribine tablets compared to HCs (15,598+11,313 vs 26,394+11,335, p<0.01). Six-month post second vaccine and 3-6 months post third vaccine there was no difference in IgG levels between the groups (1088.0 ± 1072.0 vs 1153.0 ± 997.1, p = 0.79; 5234+4097 vs 11,198+14,679, p = 0.4).
Conclusion and relevance: MS patients treated with cladribine tablets have sustained positive vaccine specific serology response following the second and third SARS-CoV-2 vaccine dose.
Keywords: COVID-19 vaccination; Cladribine tablets; Long term serology response; Multiple sclerosis.
【저자키워드】 COVID-19 vaccination, multiple sclerosis., Cladribine tablets, Long term serology response, 【초록키워드】 COVID-19, Treatment, SARS-CoV-2, Vaccine, COVID-19 vaccine, serology, mRNA vaccine, SARS-CoV-2 vaccine, vaccine dose, mRNA, immunomodulatory, Patient, group, booster, serological response, Cladribine, dose, humoral, long term, Tablet, second dose, healthy control, no difference, positive, Multiple, positive serology, significantly lower, robust, addition, maintain, sustained, receive, HCs, IgG level, patients treated, was tested, 【제목키워드】 SARS-CoV-2, mRNA vaccine, longitudinal, dose, humoral, Tablet, receiving, patients treated,